GYRE THERAPEUTICS, INC. — Form 8-K/A
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 28/100
What the filing says
On May 4, 2026, Gyre Therapeutics acquired private biopharmaceutical company Cullgen Inc. in an all-stock transaction valued at approximately $300 million. Cullgen shareholders received either common stock or Series B Convertible Preferred Stock of Gyre at an exchange ratio of 0.4753, depending on holder category. The merger was structured as a combination under common control (both entities controlled by GNI Japan pre- and post-transaction), so no goodwill was recognized; assets and liabilities transferred at historical carrying value. Cullgen had $44.6M in total assets and $132.2M accumulated deficit as of March 31, 2026.
Why this rating
Routine M&A disclosure in a Form 8-K/A. While nominally $300M, Gyre's scale (~$72.6M market cap) makes this material operationally but the SEC filing is standard post-close reporting; no new financial guidance or strategic surprise; merger already closed.
Extracted items
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.